An α-helical peptide-based plasmonic biosensor for highly specific detection of α-synuclein-toxic oligomers

Juliana Fátima Giarola,Jaime,M.-Carmen Estevez,Salvador Ventura,Irantzu Pallarès,Laura M. Lechuga
DOI: https://doi.org/10.1016/j.aca.2024.342559
IF: 6.911
2024-04-01
Analytica Chimica Acta
Abstract:Background α-Synuclein (αS) aggregation is the main neurological hallmark of a group of neurodegenerative disorders, collectively referred to as synucleinopathies, of which Parkinson's disease (PD) is the most prevalent. αS oligomers are elevated in the cerebrospinal fluid (CSF) of PD patients, standing as a biomarker for disease diagnosis. However, methods for early PD detection are still lacking. We have recently identified the amphipathic 22-residue peptide PSMα3 as a high-affinity binder of αS toxic oligomers. PSMα3 displayed excellent selectivity and reproducibility, binding to αS toxic oligomers with affinities in the low nanomolar range and without detectable cross-reactivity with functional monomeric αS. Results In this work, we leveraged these PSMα3 unique properties to design a plasmonic-based biosensor for the direct detection of toxic oligomers under label-free conditions. Significance and novelty We describe the integration of the peptide in a lab-on-a-chip plasmonic platform suitable for point-of-care measurements of αS toxic oligomers in CSF samples in real-time and at an affordable cost, providing an innovative biosensor for PD early diagnosis in the clinic.
chemistry, analytical
What problem does this paper attempt to address?